According to Nektar Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -121.10%. At the end of 2024 the company had an Operating Margin of -121.10%.
Year | Operating Margin | Change |
---|---|---|
2024 | -121.10% | -60.49% |
2023 | -306.54% | -22.69% |
2022 | -396.48% | -22.79% |
2021 | -513.49% | 76.87% |
2020 | -290.32% | -24.38% |
2019 | -383.93% | -771.07% |
2018 | 57.21% | -283.24% |
2017 | -31.22% | -66.16% |
2016 | -92.27% | 163.97% |
2015 | -34.96% | 28.9% |
2014 | -27.12% | -74.72% |
2013 | -107.28% | -49.19% |
2012 | -211.17% | 13.52% |
2011 | -186.01% | 698.31% |
2010 | -23.30% | -83.69% |
2009 | -142.88% | 266.66% |
2008 | -38.97% | 238.26% |
2007 | -11.52% | -83.71% |
2006 | -70.70% | -51.8% |
2005 | -146.70% | 64.27% |
2004 | -89.31% | 104.01% |
2003 | -43.77% | -58.52% |
2002 | -105.52% | -26.16% |
2001 | -142.90% |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.